Welcome to our dedicated page for Waters news (Ticker: WAT), a resource for investors and traders seeking the latest updates and insights on Waters stock.
Waters Corporation (NYSE: WAT) is a global leader in the field of analytical instruments and software solutions. For nearly six decades, the company has pioneered advancements in chromatography, mass spectrometry, and thermal analysis, catering to life, materials, and food sciences. Headquartered in Milford, Massachusetts, Waters Corp. operates directly in 35 countries, supported by approximately 8,000 employees and 15 manufacturing facilities globally.
Waters' main business segments include Waters, TA Instruments, VICAM, ERA, and Nonlinear Dynamics. The company's diverse product portfolio features ultra-performance liquid chromatography (UPLC), high-performance liquid chromatography (HPLC), chromatography columns, mass spectrometry systems, and laboratory informatics solutions. These innovations empower laboratory-dependent organizations to achieve advancements in healthcare, environmental management, food safety, and water quality.
Waters Corporation serves a wide array of customers, including biopharmaceutical companies (57% of sales), industrial clients (31% of sales), and academic/government institutions (12% of sales). The company’s products are available in over 100 countries, ensuring a broad market reach.
Recent achievements include the launch of new accessories for TA Instruments Discovery Hybrid Rheometers, designed for battery formulation analysis, and the introduction of Oasis WAX/GCB and GCB/WAX Cartridges for PFAS analysis. These innovations reflect the company’s commitment to addressing emerging scientific challenges and regulatory requirements. Additionally, Waters continues to enhance its mass spectrometry capabilities with products like the ACQUITY QDa II Mass Detector and the Xevo MRT MS, aimed at accelerating research in pharmaceuticals, food, chemicals, and materials.
Financially, Waters Corporation reported first-quarter 2024 sales of $637 million, with a strategic focus on innovation and operational efficiency. Despite a 7% decrease in sales compared to the previous year, the company remains optimistic about future growth, driven by new product launches and higher growth areas.
Waters Corporation stands as a pivotal player in the analytical instruments industry, consistently driving scientific advancements and operational excellence.
Waters Corporation (NYSE: WAT) reported third quarter 2021 sales of $659 million, an 11% increase from $594 million in Q3 2020. GAAP EPS rose to $2.60, up from $2.03 year-over-year. Non-GAAP EPS was $2.66, reflecting a 23% increase. Key growth drivers included a 16% rise in pharmaceutical sales and 9% in industrial markets. The company anticipates full-year 2021 sales growth of 15%-16% and non-GAAP EPS between $10.94 and $11.04. Waters also experienced strong recurring revenue growth of 11% in Q3, alongside a 10% increase in instrument sales.
Waters Corporation (NYSE: WAT) and Sartorius (DAX: SRT:GR) have announced a partnership to enhance biopharmaceutical process development. Their collaboration integrates the Waters BioAccord LC-MS System with Sartorius’ Ambr multi-parallel bioreactor systems, enabling faster access to critical quality data. This integration can reduce analysis time from several weeks to just two days, aiding scientists in clone selection and process optimization. The initiative aims to meet the growing demand for upstream analytical data in the rapidly expanding biopharmaceutical market, projected to grow at a ~10% CAGR until 2025.
Waters Corporation (NYSE:WAT) and the University of Delaware have announced a multi-year partnership aimed at enhancing analytical solutions for the biopharmaceutical industry. The collaboration will take place at Immerse Delaware, a new research lab located on the university's STAR campus, focusing on improving drug quality, yields, and manufacturing efficiency. Through this partnership, Waters and university researchers will work on projects leveraging LC-MS technologies to address significant challenges in bioprocessing, ultimately aiming to accelerate the delivery of high-quality medicines.
Waters Corporation (NYSE:WAT) will host a live webcast for its Q3 2021 financial results on November 2, 2021, at 8:00 a.m. eastern time. Investors can access the webcast via the Waters investor relations website. A replay will be available until November 16, 2021, at midnight eastern time. Waters has over 60 years of experience in chromatography and mass spectrometry, employing more than 7,400 staff across 35 countries. The company continues to lead in specialty measurement solutions for life, materials, and food sciences.
Waters Corporation (NYSE:WAT) has appointed
Waters Corporation (NYSE:WAT) has launched the BioAccord System with ACQUITY Premier, a new LC-MS system aimed at enhancing multi-attribute monitoring of biotherapeutics. This system significantly improves analyte recovery and assay reproducibility, addressing challenges posed by analyte-to-metal interactions. Expected to facilitate quicker access to mass spectrometry data, the system aims to lower costs and expedite the delivery of medicines to patients. Customer shipments are set to commence at the month’s end.
Waters Corporation (NYSE:WAT) has launched the BioAccord System with ACQUITY Premier, an advanced LC-MS system designed for improved monitoring of biotherapeutics. This system significantly enhances analyte recovery and assay reproducibility, allowing faster access to critical data about biologics. Key features include MaxPeak HPS technology, which eliminates analyte-to-metal interactions, resulting in up to 300% increase in sensitivity for glycan profiling. Shipments are expected to begin soon, which may help accelerate the delivery of essential medicines to patients.
Waters Corporation (NYSE:WAT) announced that its CEO, Udit Batra, will present at the Bank of America Global Healthcare Conference on September 16, 2021, at 3:55 PM BST (10:55 AM Eastern Time). Investors can access the live webcast on Waters' investor relations website. Waters, a leader in specialty measurement, has over 7,400 employees and operates in 35 countries, with products available in more than 100 countries.
Waters Corporation (NYSE:WAT) announced that its CEO, Udit Batra, will engage in a virtual fireside chat at Morgan Stanley’s 19th Annual Global Healthcare event on September 14th, 2021, at 8:45 AM EST. Investors can access the live webcast through Waters’ investor relations website. Waters has been a leader in chromatography and mass spectrometry for over 60 years, with more than 7,400 employees across 35 countries.
Waters Corporation reported a strong second quarter 2021 with sales reaching $682 million, a 31% increase from $520 million a year prior, driven by a 4% boost from foreign currency translation. GAAP diluted EPS rose to $2.69 from $1.98 in Q2 2020. For the first half of 2021, sales grew to $1,290 million, with 31% growth compared to the same period last year. The company anticipates full-year sales growth between 13% to 15% and expects non-GAAP EPS of $10.50 to $10.70.
FAQ
What is the current stock price of Waters (WAT)?
What is the market cap of Waters (WAT)?
What industries does Waters Corporation serve?
What are some of Waters Corporation's recent product launches?
How does Waters Corporation contribute to scientific advancements?
What is the significance of the TA Instruments Discovery Hybrid Rheometers?
How is Waters Corporation performing financially?
Where is Waters Corporation headquartered?
How many employees does Waters Corporation have?
What are TA Instruments' main products?
What is the significance of the Oasis WAX/GCB Cartridges?
How can I access Waters Corporation's financial results?
